关于高血压脏病的分子机制的审查
Zhen Peng1, Qiaohong Xu1, Wen Hu1
1Department of Pharmacy, Yichun People's Hospital, Yichun, Jiangxi 336000, China.
Current pharmaceutical design
|November 6, 2023
概括
高血压会损害脏,导致高血压性脏病,这是功能衰竭的主要原因. 本综述探讨了这种疾病背后的分子机制,以改善诊断和治疗.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 分子生物学分子生物学
- 心血管疾病 心血管疾病
背景情况:
- 高血压是一种常见的疾病,可能导致脏损伤,称为高血压脏病.
- 高血压脏病是末期脏病的日益严重的原因,特别是在老龄化城市人口中.
- 高血压性病的复杂发展使临床诊断和治疗复杂化.
研究的目的:
- 审查当前关于高血压脏病发病的研究.
- 专注于高血压脏病发展的分子生物学方面.
- 为改善诊断和治疗策略提供基础.
主要方法:
- 关于高血压脏病的研究的文献综述.
- 分析涉及高血压导致损伤的分子和细胞机制.
- 来自遗传学,生化学和生理学研究的研究结果的综合.
主要成果:
- 高血压会诱导脏中的分子变化,包括炎症,氧化应激和内皮功能障碍.
- 遗传因素和表观遗传修饰在高血压脏病的进展中起作用.
- 特定的分子通路,如氨酸- ангиотензин- 氨酸系统,在疾病发展中至关重要.
结论:
- 了解高血压性病的分子病原体对于开发向疗法至关重要.
- 对分子通路的进一步研究可能会导致用于早期诊断的新生物标志物.
- 针对分子机制的干预可以预防或减缓高血压脏病的进展.
相关概念视频
Hypertension II: Pathophysiology
13
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
13
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
659
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
659
Antihypertensive Drugs: Action of β1 Blockers
455
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
455
Antihypertensive Drugs: Direct Renin Inhibitors
648
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
648


